EUSOL BIOTECH CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.99 TWD | -1.10% |
|
+2.39% | -4.97% |
| Apr. 17 | Eusol Biotech Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | Eusol Biotech Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
| Sales 2022 | - | Sales 2023 | - | Capitalization | 1.3B 42.19B |
|---|---|---|---|---|---|
| Net income 2022 | -18M -586M | Net income 2023 | -51M -1.66B | EV / Sales 2022 | - |
| Net cash position 2022 | 389M 12.66B | Net cash position 2023 | 375M 12.22B | EV / Sales 2023 | - |
| P/E ratio 2022 |
-60.6
x | P/E ratio 2023 |
-25.1
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 67.23% |
More Fundamentals
* Assessed data
More news
| 1 day | -1.10% | ||
| 1 week | +2.39% | ||
| Current month | -7.22% | ||
| 1 month | -0.66% | ||
| 3 months | -11.43% | ||
| Current year | -4.97% |
1 week
8.55
9.10
1 month
8.5010.05
Current year
8.5011.20
1 year
8.5013.60
3 years
6.4529.25
5 years
6.4537.45
10 years
6.4554.00
| Managers | Title | Age | Since |
|---|---|---|---|
Hong Jen Chang
CEO | Chief Executive Officer | 68 | 09-10-04 |
Chun Yue Lin
DFI | Director of Finance/CFO | - | - |
Wan Ya Chang
BRD | Director/Board Member | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Shih Chang Hsu
BRD | Director/Board Member | 61 | - |
Hong Jen Chang
CEO | Chief Executive Officer | 68 | 09-10-04 |
Tsung Jen Yang
BRD | Director/Board Member | - | 18-06-14 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 8.99 | -1.10% | 23 520 |
| 24-04-24 | 9.09 | 0.00% | 100 |
| 24-04-23 | 9.09 | 0.00% | 9,400 |
| 24-04-22 | 9.09 | +1.00% | 1,460 |
| 24-04-19 | 9 | +0.56% | 125,672 |
End-of-day quote Taipei Exchange, April 24, 2024
More quotes
EUSOL Biotech CO., LTD. is a Taiwan-based company mainly engaged in production of drugs. The Company is mainly engaged in the research, development and production of drugs. The Company is also engaged in cosmetics manufacturing business, drug testing business and western medicine retail business. The Company's main products include the protein drug ES135 and the small molecule compound drug SM-1. The Company distributes its products within domestic and overseas markets.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| -4.97% | 38.13M | |
| +24.17% | 562B | |
| -6.23% | 358B | |
| +20.09% | 322B | |
| +7.66% | 297B | |
| +13.45% | 219B | |
| +6.04% | 199B | |
| -10.51% | 196B | |
| -12.07% | 149B | |
| -6.40% | 146B |
- Stock Market
- Equities
- 6652 Stock
